123 related articles for article (PubMed ID: 34254615)
1. Combined therapy of ruthenium dendrimers and anti-cancer drugs against human leukemic cells.
Michlewska S; Maroto M; Hołota M; Kubczak M; Sanz Del Olmo N; Ortega P; Shcharbin D; de la Mata FJ; Bryszewska M; Ionov M
Dalton Trans; 2021 Jul; 50(27):9500-9511. PubMed ID: 34254615
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium dendrimers as carriers for anticancer siRNA.
Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Loznikova S; Shcharbin D; Maly M; Ramirez RG; de la Mata FJ; Bryszewska M
J Inorg Biochem; 2018 Apr; 181():18-27. PubMed ID: 29353086
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium Dendrimers against Human Lymphoblastic Leukemia 1301 Cells.
Michlewska S; Ionov M; Szwed A; Rogalska A; Sanz Del Olmo N; Ortega P; Denel M; Jacenik D; Shcharbin D; de la Mata FJ; Bryszewska M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526993
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium dendrimers against acute promyelocytic leukemia:
Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Abashkin V; Dzmitruk V; Rogalska A; Denel M; Gapinska M; Shcharbin D; Gomez Ramirez R; de la Mata FJ; Bryszewska M
Future Med Chem; 2019 Jul; 11(14):1741-1756. PubMed ID: 31287722
[TBL] [Abstract][Full Text] [Related]
5. Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocols.
Michlewska S; Garaiova Z; Šubjakova V; Hołota M; Kubczak M; Grodzicka M; Okła E; Naziris N; Balcerzak Ł; Ortega P; de la Mata FJ; Hianik T; Waczulikova I; Bryszewska M; Ionov M
Colloids Surf B Biointerfaces; 2023 Jul; 227():113371. PubMed ID: 37244201
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.
Maroto-Díaz M; Elie BT; Gómez-Sal P; Pérez-Serrano J; Gómez R; Contel M; Javier de la Mata F
Dalton Trans; 2016 Apr; 45(16):7049-66. PubMed ID: 26990859
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.
Michlewska S; Kubczak M; Maroto-Díaz M; Sanz Del Olmo N; Ortega P; Shcharbin D; Gomez Ramirez R; Javier de la Mata F; Ionov M; Bryszewska M
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450702
[TBL] [Abstract][Full Text] [Related]
8. Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study.
Michlewska S; Maly M; Wójkowska D; Karolczak K; Skiba E; Hołota M; Kubczak M; Ortega P; Watala C; Javier de la Mata F; Bryszewska M; Ionov M
Int J Pharm; 2023 Apr; 636():122784. PubMed ID: 36858135
[TBL] [Abstract][Full Text] [Related]
9. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.
Sanz Del Olmo N; Bajo AM; Ionov M; García-Gallego S; Bryszewska M; Gómez R; Ortega P; de la Mata FJ
Eur J Med Chem; 2020 Aug; 199():112414. PubMed ID: 32438200
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs.
Kojima C; Kono K; Maruyama K; Takagishi T
Bioconjug Chem; 2000; 11(6):910-7. PubMed ID: 11087341
[TBL] [Abstract][Full Text] [Related]
11. Carbosilane dendrimers are a non-viral delivery system for antisense oligonucleotides: characterization of dendriplexes.
Pedziwiatr-Werbicka E; Shcharbin D; Maly J; Maly M; Zaborski M; Gabara B; Ortega P; de la Mata FJ; Gómez R; Muñoz-Fernandez MA; Klajnert B; Bryszewska M
J Biomed Nanotechnol; 2012 Feb; 8(1):57-73. PubMed ID: 22515094
[TBL] [Abstract][Full Text] [Related]
12. Novel Water-Soluble Mucoadhesive Carbosilane Dendrimers for Ocular Administration.
Bravo-Osuna I; Vicario-de-la-Torre M; Andrés-Guerrero V; Sánchez-Nieves J; Guzmán-Navarro M; de la Mata FJ; Gómez R; de Las Heras B; Argüeso P; Ponchel G; Herrero-Vanrell R; Molina-Martínez IT
Mol Pharm; 2016 Sep; 13(9):2966-76. PubMed ID: 27149661
[TBL] [Abstract][Full Text] [Related]
13. Polyphenolic dendrimers as carriers of anticancer siRNA.
Grodzicka M; Michlewska S; Blasiak J; Ortega P; de la Mata FJ; Bryszewska M; Ionov M
Int J Pharm; 2024 Jun; 658():124199. PubMed ID: 38703928
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Interactions of Ruthenium (II) Carbosilane Metallodendrimers and Precursors with Model Cell Membranes through a Dual Spin-Label Spin-Probe Technique Using EPR.
Carloni R; Sanz Del Olmo N; Ortega P; Fattori A; Gómez R; Ottaviani MF; García-Gallego S; Cangiotti M; de la Mata FJ
Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31569790
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of a charge-conversional dendrimer enhances antitumor efficacy of conventional chemotherapy.
Cao J; Wang C; Guo L; Xiao Z; Liu K; Yan H
Eur J Pharm Biopharm; 2018 Jun; 127():371-377. PubMed ID: 29499301
[TBL] [Abstract][Full Text] [Related]
16. Anti-Human Immunodeficiency Virus Activity of Thiol-Ene Carbosilane Dendrimers and Their Potential Development as a Topical Microbicide.
Sánchez-Rodríguez J; Díaz L; Galán M; Maly M; Gómez R; Javier de la Mata F; Jiménez JL; Muñoz-Fernández MA
J Biomed Nanotechnol; 2015 Oct; 11(10):1783-98. PubMed ID: 26502641
[TBL] [Abstract][Full Text] [Related]
17. Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer.
Sanz Del Olmo N; Maroto-Diaz M; Quintana S; Gómez R; Holota M; Ionov M; Bryszewska M; Carmena MJ; Ortega P; Javier de la Mata F
Eur J Med Chem; 2020 Dec; 207():112695. PubMed ID: 32882608
[TBL] [Abstract][Full Text] [Related]
18. Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery.
Sharma AK; Gothwal A; Kesharwani P; Alsaab H; Iyer AK; Gupta U
Drug Discov Today; 2017 Feb; 22(2):314-326. PubMed ID: 27671487
[TBL] [Abstract][Full Text] [Related]
19. Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation.
Wang F; Cai X; Su Y; Hu J; Wu Q; Zhang H; Xiao J; Cheng Y
Acta Biomater; 2012 Dec; 8(12):4304-13. PubMed ID: 22842039
[TBL] [Abstract][Full Text] [Related]
20. Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models.
Hołota M; Michlewska S; Garcia-Gallego S; Del Olmo NS; Ortega P; Bryszewska M; de la Mata FJ; Ionov M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
